BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 32232506)

  • 21. LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma.
    Keane C; Law SC; Gould C; Birch S; Sabdia MB; Merida de Long L; Thillaiyampalam G; Abro E; Tobin JW; Tan X; Xu-Monette ZY; Young KH; Gifford G; Gabreilli S; Stevenson WS; Gill A; Talaulikar D; Jain S; Hernandez A; Halliday SJ; Bird R; Cross D; Hertzberg M; Gandhi MK
    Blood Adv; 2020 Apr; 4(7):1367-1377. PubMed ID: 32267932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic Value of Tumor Proportion Score in Salivary Gland Carcinoma.
    Sato F; Ono T; Kawahara A; Matsuo K; Kondo R; Sato K; Akiba J; Kawaguchi T; Kakuma T; Chitose SI; Umeno H; Yano H
    Laryngoscope; 2021 May; 131(5):E1481-E1488. PubMed ID: 33022760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Role of Molecular Testing in the Differential Diagnosis of Salivary Gland Carcinomas.
    Skálová A; Stenman G; Simpson RHW; Hellquist H; Slouka D; Svoboda T; Bishop JA; Hunt JL; Nibu KI; Rinaldo A; Vander Poorten V; Devaney KO; Steiner P; Ferlito A
    Am J Surg Pathol; 2018 Feb; 42(2):e11-e27. PubMed ID: 29076877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LAG-3, TIM-3 and VISTA Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma-Potential Biomarkers for Targeted Therapy Concepts.
    Wuerdemann N; Pütz K; Eckel H; Jain R; Wittekindt C; Huebbers CU; Sharma SJ; Langer C; Gattenlöhner S; Büttner R; Speel EJ; Suchan M; Wagner S; Quaas A; Klussmann JP
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
    He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR
    J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The expression of the adenosine pathway markers CD39 and CD73 in salivary gland carcinomas harbors the potential for novel immune checkpoint inhibition.
    Bauer A; Gebauer N; Knief J; Tharun L; Arnold N; Riecke A; Steinestel K; Witte HM
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3193-3208. PubMed ID: 35902382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma.
    Tavares MC; Sampaio CD; Lima GE; Andrade VP; Gonçalves DG; Macedo MP; Cordeiro de Lima VC
    BMC Cancer; 2021 Aug; 21(1):901. PubMed ID: 34362334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The expression profiles of signature genes from CD103
    Xia ZA; Lu C; Pan C; Li J; Li J; Mao Y; Sun L; He J
    BMC Med; 2023 Jul; 21(1):268. PubMed ID: 37488535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A TP53-based immune prognostic model for muscle-invasive bladder cancer.
    Li H; Lu H; Cui W; Huang Y; Jin X
    Aging (Albany NY); 2020 Dec; 13(2):1929-1946. PubMed ID: 33323544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of cancer/testis antigens in salivary gland carcinomas with reference to MAGE-A and NY-ESO-1 expression in adenoid cystic carcinoma.
    Beppu S; Ito Y; Fujii K; Saida K; Takino H; Masaki A; Murase T; Kusafuka K; Iida Y; Onitsuka T; Yatabe Y; Hanai N; Hasegawa Y; Ijichi K; Murakami S; Inagaki H
    Histopathology; 2017 Aug; 71(2):305-315. PubMed ID: 28370175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathological correlation of Cathepsin K expression in salivary gland carcinomas; relation to patients` outcome.
    Elhendawy HA; Soliman S
    Diagn Pathol; 2023 May; 18(1):66. PubMed ID: 37198626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry.
    Park Y; Seo AN; Koh J; Nam SK; Kwak Y; Ahn SH; Park DJ; Kim HH; Lee HS
    Oncoimmunology; 2021; 10(1):1954761. PubMed ID: 34367732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpression of sphingosine kinase 1 is associated with salivary gland carcinoma progression and might be a novel predictive marker for adjuvant therapy.
    Liu G; Zheng H; Zhang Z; Wu Z; Xiong H; Li J; Song L
    BMC Cancer; 2010 Sep; 10():495. PubMed ID: 20846391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Colorectal Cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival.
    Sorrentino C; D'Antonio L; Fieni C; Ciummo SL; Di Carlo E
    Front Immunol; 2021; 12():778329. PubMed ID: 34975867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lymphocyte-activated gene-3 (LAG3) protein expressed in tumor-infiltrating lymphocytes of colorectal cancer.
    Xu J; Shen D; Zhang T; Wang J; De W; Zhang J
    Pol J Pathol; 2021; 72(4):324-330. PubMed ID: 35308003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trophoblast Cell Surface Antigen 2 (Trop-2) Protein is Highly Expressed in Salivary Gland Carcinomas and Represents a Potential Therapeutic Target.
    Wolber P; Nachtsheim L; Hoffmann F; Klußmann JP; Meyer M; von Eggeling F; Guntinas-Lichius O; Quaas A; Arolt C
    Head Neck Pathol; 2021 Dec; 15(4):1147-1155. PubMed ID: 33886073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas.
    Mukaigawa T; Hayashi R; Hashimoto K; Ugumori T; Hato N; Fujii S
    J Surg Oncol; 2016 Jul; 114(1):36-43. PubMed ID: 27111278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies.
    Ross JS; Gay LM; Wang K; Vergilio JA; Suh J; Ramkissoon S; Somerset H; Johnson JM; Russell J; Ali S; Schrock AB; Fabrizio D; Frampton G; Miller V; Stephens PJ; Elvin JA; Bowles DW
    Ann Oncol; 2017 Oct; 28(10):2539-2546. PubMed ID: 28961851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences in Immunological Landscape between
    Luo JW; Guo YH; Wu FY; Li XF; Sun XC; Wang JL; Zhou CC
    Dis Markers; 2021; 2021():3776854. PubMed ID: 34484468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.
    Bottai G; Raschioni C; Losurdo A; Di Tommaso L; Tinterri C; Torrisi R; Reis-Filho JS; Roncalli M; Sotiriou C; Santoro A; Mantovani A; Loi S; Santarpia L
    Breast Cancer Res; 2016 Dec; 18(1):121. PubMed ID: 27912781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.